| Literature DB >> 26070486 |
Clément Jacquemin1, Nathalie Schmitt2, Cécile Contin-Bordes3, Yang Liu2, Priya Narayanan2, Julien Seneschal3, Typhanie Maurouard2, David Dougall2, Emily Spence Davizon2, Hélène Dumortier4, Isabelle Douchet5, Loïc Raffray6, Christophe Richez3, Estibaliz Lazaro3, Pierre Duffau3, Marie-Elise Truchetet3, Liliane Khoryati1, Patrick Mercié7, Lionel Couzi7, Pierre Merville3, Thierry Schaeverbeke7, Jean-François Viallard7, Jean-Luc Pellegrin7, Jean-François Moreau3, Sylviane Muller8, Sandy Zurawski2, Robert L Coffman9, Virginia Pascual2, Hideki Ueno10, Patrick Blanco11.
Abstract
Increased activity of T follicular helper (Tfh) cells plays a major pathogenic role in systemic lupus erythematosus (SLE). However, the mechanisms that cause aberrant Tfh cell responses in SLE remain elusive. Here we showed the OX40 ligand (OX40L)-OX40 axis contributes to the aberrant Tfh response in SLE. OX40L was expressed by myeloid antigen-presenting cells (APCs), but not B cells, in blood and in inflamed tissues in adult and pediatric SLE patients. The frequency of circulating OX40L-expressing myeloid APCs positively correlated with disease activity and the frequency of ICOS(+) blood Tfh cells in SLE. OX40 signals promoted naive and memory CD4(+) T cells to express multiple Tfh cell molecules and were sufficient to induce them to become functional B cell helpers. Immune complexes containing RNA induced OX40L expression on myeloid APCs via TLR7 activation. Our study provides a rationale to target the OX40L-OX40 axis as a therapeutic modality for SLE.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26070486 PMCID: PMC4570857 DOI: 10.1016/j.immuni.2015.05.012
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745